【low bromine in salt water pool】SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Lexicon Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline – LXRX
NEW YORK,low bromine in salt water pool NY / ACCESSWIRE / January 31, 2019 /
Pomerantz LLP announces that a class action lawsuit has been filed against Lexicon Pharmaceuticals, Inc. ("Lexicon" or the "Company") (
LXRX
) and certain of its officers and directors. The class action, filed in United States District Court, Southern District of Texas, and indexed under 19-cv-00301, is on behalf of a class consisting of all behalf of persons and/or entities who purchased or otherwise acquired Lexicon securities between March 11, 2016 and January 17, 2019, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
If you are a shareholder who purchased Lexicon securities between March 11, 2016, and January 17, 2019, you have until April 1, 2019, to ask the Court to appoint you as Lead Plaintiff for the class. A copy of the Complaint can be obtained at
www.pomerantzlaw.com
. To discuss this action, contact Robert S. Willoughby at
or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext. 9980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
[Click here to join this class action]
Lexicon was founded in 1995 and is headquartered in The Woodlands, Texas. Lexicon is a biopharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of human diseases.
"Sotagliflozin" is the scientific name of one of Lexicon's orally-delivered small molecule drug candidates under development. Sotagliflozin is in Phase 3 clinical trials for the treatment of type 1 and type 2 diabetes.
In November 2015, Lexicon entered into a collaboration and license agreement with Sanofi S.A. ("Sanofi"), a French multinational pharmaceutical company. Under the collaboration and license agreement, Lexicon granted Sanofi an exclusive, worldwide, royalty-bearing right and license to develop, manufacture and commercialize Sotagliflozin. Lexicon is responsible for all clinical development activities relating to type 1 diabetes and retains an exclusive option to co-promote and have a significant role, in collaboration with Sanofi, in the commercialization of Sotagliflozin for the treatment of type 1 diabetes in the United States. Sanofi is responsible for all clinical development and commercialization of Sotagliflozin for the treatment of type 2 diabetes worldwide and is solely responsible for the commercialization of Sotagliflozin for the treatment of type 1 diabetes outside the United States.
On May 22, 2018, Sanofi filed a New Drug Application ("NDA") for "Zynquista" (the trademarked, commercialized name of Sotagliflozin) with the U.S. Food and Drug Administration ("FDA"). The NDA for Zynquista was based on data from the inTandem clinical trial program that included three Phase 3 clinical trials (called, respectively, "inTandem1," "inTandem2," and "inTandem3") assessing the safety and efficacy of Zynquista in approximately 3,000 adults with inadequately controlled type 1 diabetes.
According to Jorge Insuasty, Senior-Vice President, Global Head of Development, Sanofi, "[i]f approved, Zynquista would be the first oral antidiabetic drug approved in the U.S. for use by adults with type 1 diabetes, in combination with insulin."
The complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operational and compliance policies. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) the data from Lexicon's Phase 3 clinical trials assessing the safety and efficacy of Sotagliflozin in treating type 1 diabetes were not as positive as Lexicon represented; (ii) the health risks posed by Sotagliflozin were severe enough to threaten its FDA approval prospects; and (iii) as a result, Lexicon's public statements were materially false and misleading at all relevant times.
On January 17, 2019, Lexicon announced that the Endocrinologic and Metabolic Drugs Advisory Committee of the FDA (the "Advisory Committee") had "voted eight to eight on the question of whether the overall benefits of [Lexicon's product] Zynquista (sotagliflozin) outweighed the risks to support approval."
On news of the Advisory Committee's stalemate, Lexicon's stock price fell $1.74 per share, or 22.6%, to close at $5.96 per share on January 18, 2019.
The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See
www.pomerantzlaw.com
SOURCE:
Pomerantz LLP
View source version on accesswire.com:
https://www.accesswire.com/534155/SHAREHOLDER-ALERT-Pomerantz-Law-Firm-Reminds-Shareholders-with-Losses-on-their-Investment-in-Lexicon-Pharmaceuticals-Inc-of-Class-Action-Lawsuit-and-Upcoming-Deadline-LXRX
View comments
-
IIOT-OXYS, Provides Business Update on COVID-19Market Sentiment Improves As Investors Pin Hopes on G7 ActionNatural Gas Price Fundamental Weekly Forecast – Heating Season Begins with Hedge Funds Holding Long PositionsAre Insiders Buying Arena Events Group plc (LON:ARE) Stock?How Good Is Harvia Oyj (HEL:HARVIA), When It Comes To ROE?Why Prosperity Bancshares (PB) is a Top Dividend Stock for Your PortfolioIs housing a better investment than education?35 Surprising Cities With Low Costs of LivingCan Guess (GES) Keep the Earnings Surprise Streak Alive?EXPLAINER-Why automakers are on a drive to sell electric cars in Europe
下一篇:Calculating The Fair Value Of Motorola Solutions, Inc. (NYSE:MSI)
- ·Elwood Global becomes largest blockchain ETF with $95.4 million in total assets
- ·Weekly CEO Buys Highlight
- ·Investview (INVU) Reports Record $1.4 Million Month Bitcoin Mining Revenue and Increased Bitcoin Holdings
- ·Agios' (AGIO) Phase III Study on Mitapivat Meets Primary Goal
- ·John B. Sanfilippo & Son, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
- ·The Global Virtualization in Industrial Automation Market is expected to grow by $ 216.39 mn during 2020-2024 progressing at a CAGR of 4% during the forecast period
- ·A Magnificent Ascent For The Newest Cloud ETF
- ·Expanse Integrates with ServiceNow
- ·Brazil manufacturing PMI rises to 38.3 in May from record low 36.0 in April - IHS Markit
- ·Domino's (DPZ) Opens 17,000th Store, Expands in Australia
- ·Drone Delivery Canada Begins Flights For First Paying Customer
- ·UK to extend furlough scheme beyond Dec. as BOE pumps in 150bln pounds - The Sun
- ·Skyworks Solutions (SWKS) Matches Q2 Earnings Estimates
- ·Berkshire Hathaway annual meeting 2020: 5 things to know
- ·SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spirit AeroSystems Holdings, Inc. - SPR
- ·Exclusive: StanChart says CEO Winters will stay to execute current strategy
- ·Are Options Traders Betting on a Big Move in Penn National (PENN) Stock?
- ·How to Rise Above an ACT, SAT Test Score Plateau
- ·Bioreactors Market Research Report by Material, by Usage, by Scale, by Control Type, by Distrbution - Global Forecast to 2025 - Cumulative Impact of COVID-19
- ·INVESTOR APRIL DEADLINE REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Aaron's, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- ·This Broker Just Slashed Their Freelance.com SA (EPA:ALFRE) Earnings Forecasts
- ·A Sliding Share Price Has Us Looking At Malibu Boats, Inc.'s (NASDAQ:MBUU) P/E Ratio
- ·IIOT-OXYS, Provides Business Update on COVID-19
- ·SNX or GWRE: Which Is the Better Value Stock Right Now?
- ·Stericycle (SRCL) Tops Q3 Earnings and Revenue Estimates
- ·EXPLAINER-Why automakers are on a drive to sell electric cars in Europe
- ·Ferrari (RACE) Q3 Earnings Beat Estimates
- ·Used Construction Equipment Market to hit USD 142 Bn by 2026: Global Market Insights, Inc.
- ·Why Is Maximus (MMS) Down 12.8% Since Last Earnings Report?
- ·EPR Properties: 3Q Earnings Snapshot
- ·US colleges in the crosshairs as coronavirus fears swirl
- ·Global Care Capital Portfolio Company ViraxClear Secures Supply Contracts to Meet Demand for COVID-19 Antibody Test Kits in Europe and Singapore
- ·Mike Bloomberg thinks a gun-control pitch works … in Texas
- ·5 High-Yield Stocks to Defy Coronavirus-Led Crisis in April
- ·Stericycle (SRCL) Tops Q3 Earnings and Revenue Estimates
- ·Founder Alexander Reilley Just Bought 10.0% More Shares In Loungers plc (LON:LGRS)